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Abstract
Background: Surfactant dysfunction due to inhibition is involved in the pathophysiology of
meconium aspiration syndrome. Dextran addition has been shown to reverse exogenous
surfactant inactivation by meconium, but the precise mechanisms and the morphological correlate
of this effect are yet unknown. Morphological surfactant analysis by transmission electron
microscopy (TEM) and stereology allows the differentiation of active (large aggregates = LA) and
inactive (small aggregates = SA) subtypes.
Methods: To determine the in vitro effects of meconium and dextran addition on the morphology
of a modified porcine natural surfactant (Curosurf), Curosurf samples were either incubated alone
or together with meconium or with meconium and dextran, fixed and processed for TEM. Volume
fractions of surfactant subtypes [lamellar body-like forms (LBL), multilamellar vesicles (MV),
unilamellar vesicles (UV)] were determined stereologically.
Results: All preparations contained LBL and MV (corresponding to LA) as well as UV
(corresponding to SA). The volume fraction of UV increased with addition of meconium and
decreased with further addition of dextran. Correspondingly, the UV/(LBL+MV) ratio (resembling
the SA/LA ratio) increased when meconium was added and decreased when dextran was added to
the surfactant-meconium mixture.
Conclusion: Meconium causes alterations in the ultrastructural composition of Curosurf that can
be visualized and analyzed by TEM and stereology. These alterations resemble an increase in the
SA/LA ratio and are paralleled by an increase in minimum surface tension. Dextran prevents these
effects and may therefore be a useful additive to exogenous surfactant preparations to preserve
their structural and functional integrity, thereby improving their resistance to inactivation.
Background
The surfactant system of the lung prevents alveolar col-
lapse by reducing alveolar surface tension. Growing evi-
dence suggests that certain surfactant components also
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sized and secreted by type II alveolar epithelial cells, is a
complex mixture of lipids, mainly saturated phospholip-
ids, and proteins, among them the surfactant apoproteins
SP-A, -B, -C and -D [1]. The two hydrophilic, large molec-
ular weight surfactant apoproteins SP-A and SP-D are lost
during extraction with organic solvents used in the pro-
duction of the commercially available surfactant prepara-
tions of bovine or porcine origin. The glycoproteins SP-A
and SP-D are members of the collectin family and seem to
"orchestrate the lung's immune response" [2,3]. In con-
trast, the hydrophobic surfactant proteins SP-B and SP-C
are contained in natural modified surfactants for clinical
use. SP-B and SP-C are essential for the biophysical activ-
ity of surfactant preparations [4,5].
Intraalveolar surfactant is present in different morpholog-
ical forms which, according to current models, corre-
spond to different stages within surfactant metabolism
[6]. Surfactant material is secreted by type II cells as lamel-
lar bodies. Within the hypophase of the alveolar lining
layer, lamellar body-like forms undergo transformation
into tubular myelin figures when SP-A is added to their
outer lamellae [7]. Tubular myelin is thought to be the
precursor of material that is inserted into the surface film.
"Spent" surfactant is found in the hypophase as unilamel-
lar vesicles and can be taken up by type II cells. After dif-
ferential centrifugation of intraalveolar surfactant
material obtained by bronchoalveolar lavage, surface
active large aggregates (LA), largely corresponding to
lamellar body-like forms, tubular myelin and multilamel-
lar vesicles, and inactive small aggregates (SA), largely cor-
responding to unilamellar vesicles, can be distinguished
[8-10].
Several studies indicate that dysfunction of pulmonary
surfactant due to inhibition plays a key role in the patho-
physiology of meconium aspiration syndrome [11-15].
Thus, there is a rationale for exogenous surfactant therapy
in neonates with severe respiratory failure due to meco-
nium aspiration [16-21]. In vitro, meconium inhibits
exogenous surfactant preparations in a dose-dependent
manner [22]and alters exogenous surfactant morphology
[23]. The addition of nonionic polymers like dextran has
been shown to reverse the inactivation of exogenous sur-
factant by meconium in vitro [24-26]. This and other in
vitro and in vivo findings [27-30]have led to the concept
that surfactant inactivation in various forms of acute lung
injury may be overcome with the help of nonionic poly-
mers [31]. However, the precise mechanisms and the mor-
phological correlate of these effects are yet unknown.
Inactivation of intraalveolar surfactant in acute lung
injury and related conditions includes increased conver-
sion of surface active LA to SA with poor surface activity.
The SA/LA ratio of surfactant material obtained by bron-
choalveolar lavage is therefore used to assess the biophys-
ical activity of the endogenous surfactant system
[8,10,32]. These two different functional states within sur-
factant metabolism correspond to different surfactant
subtypes that can be distinguished morphologically at the
electron microscopical level. Using a transmission elec-
tron microscopical and stereological approach, active and
inactive intraalveolar surfactant subtypes can be analyzed
qualitatively and quantitatively in their natural localiza-
tion and microorganization within the lung. Ultrastruc-
tural alterations resembling an increase in the SA/LA ratio
have been demonstrated in various forms of acute lung
injury [33-35]. A stereological approach has also been
used to analyze exogenous surfactant preparations
[36,37], but so far, it has not been applied to investigate
meconium inhibition of exogenous surfactants.
Therefore, the aim of the present study was to analyze the
in vitro effects of meconium and dextran addition on the
morphology of a modified porcine natural surfactant
(Curosurf) by means of transmission electron microscopy
and to quantitate active and inactive subtypes by stereol-
ogy.
Methods
Meconium, surfactant, dextran
Meconium from 16 healthy term neonates was collected,
lyophilised and pooled following parental consent and
approval of the study by the local ethics committee. 49.4
g of the material had a dry weight of 12.2 g (i.e. water con-
tent: 75.3%) following lyophylization. For our studies all
materials were resuspended/diluted in saline containing
1.5 mmol/l CaCl2 to reach a meconium concentration of
0.04 or 0.6 mg/ml (wt/vol), a surfactant (Curosurf, Batch
No.: 194/09 original concentration: 80 mg/ml, a kind gift
from Nycomed Pharma, Unterschleissheim, Germany)
concentration of 10 mg/ml and a dextran (Dextran T 500
(MW 500,000 Da), Pharmacia LKB, Uppsala, Sweden)
concentration of 10 mg/ml or 20 mg/ml, respectively. For
the final experiments the different components were
mixed, thereby reaching final concentrations of 2.5 mg/
ml surfactant, 0.02 or 0.3 mg/ml meconium and 5 or 10
mg/ml of dextran, respectively.
Fixation and processing for electron microscopy
Curosurf samples (2.5 mg/ml) were either incubated
alone or together with meconium or with meconium and
dextran for 30 min at 37°C before analysis. Samples con-
taining Curosurf (C), Curosurf + meconium 0.02 mg/ml
(CM0.02), Curosurf + meconium 0.3 mg/ml (CM0.3),
Curosurf + meconium 0.3 mg/ml + dextran 5 mg/ml
(CM0.3D5), and Curosurf + meconium 0.3 mg/ml + dex-
tran 10 mg/ml (CM0.3D10) were fixed and processed for
transmission electron microscopy.Page 2 of 8
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glutaraldehyde and 1.5% formaldehyde (made from
freshly depolymerized paraformaldehyde) in 0.15 M
Hepes buffer, pelleted by centrifugation with a 5417/R
centrifuge (Eppendorf, Hamburg, Germany) at 10,600 g
for 10 min, postfixed in 1% OsO4 in 0.1 M sodium
cacodylate, bloc-stained in half-saturated aqueous uranyl
acetate over night, dehydrated in an ascending series of
acetone and embedded in araldite [see [38]].
Ultrathin sections from 2–3 samples per group were coun-
terstained with lead citrate and analyzed qualitatively and
quantitatively at an EM 900 transmission electron micro-
scope (Leo, Oberkochen, Germany) at an accelerating
voltage of 50 kV.
Stereological analysis
Volume fractions of surfactant subtypes [lamellar body-
like forms (LBL), multilamellar vesicles (MV), unilamellar
vesicles (UV)] were determined stereologically by point
counting in systematic uniform random test fields distrib-
uted over the whole section. Between 100 and 200 count-
ing events per ultrathin section were generated to ensure
that the total observed variability was dominated by the
biological variability among samples and not by the vari-
ability among stereological measurements within one
sample [39].
Surface tension measurements
Surface tension was determined in vitro using a pulsating
bubble [40]surfactometer (Electronetics corporation, Buf-
falo, New York). In short, a small volume of fluid was
transferred into a sample chamber and an air bubble was
created. During a 30 sec adsorption period, the surface
active material forms a film at the air-liquid interface. Pul-
sation is started at a frequency of 20 cycles/min by which
the bubble undergoes cyclic area compression (50 % of
the surface area). Surface tension at minimum bubble size
(γmin) after 5 min of pulsation at a temperature of 37°C is
calculated by a computer program from the preset bubble
radius and the recorded pressure across the bubble wall
making use of the law of Laplace [40].
Results
Electron microscopy
Since the biochemical composition of endogenous sur-
factant and commercially available exogenous surfactant
preparations is different [36], there are also morphologi-
cal differences between intraalveolar surfactant subtypes
and exogenous surfactants. Due to the lack of SP-A, exog-
enous surfactants do not contain tubular myelin. Other
surfactant subtypes, however, were found in Curosurf that
can be compared to endogenous surfactant subtypes.
Three morphologically different subtypes could be distin-
guished in Curosurf samples: lamellar body-like forms
(LBL), multilamellar vesicles (MV), and unilamellar vesi-
cles (UV) (Fig. 1A).
All Curosurf-meconium preparations with or without
dextran contained LBL, MV and UV, however in varying
amounts (Fig. 2A–D). In accordance with previous studies
on intraalveolar surfactant ultrastructure [34]and current
models of surfactant metabolism [8-10], we classified LBL
and MV as LA and UV as SA for subsequent stereological
analysis.
Stereology
The stereological results are summarized in Table 1 and
illustrated in Figure 3A. The volume fraction of UV
increased with addition of meconium (C: 27%; CM0.02:
34%; CM0.3: 39%) and decreased to control values with
further addition of dextran (CM0.3D5: 30%; CM0.3D10:
28%). Correspondingly, the UV/(LBL+MV) ratio (resem-
bling the SA/LA ratio) increased when meconium was
added (C: 0.37; CM0.02: 0.51; CM0.3: 0.65) and
decreased to control values when dextran was added to
the surfactant-meconium mixture (CM0.3D5: 0.43;
CM0.3D10: 0.38).
Ultrastructure of CurosurfFigure 1
Ultrastructure of Curosurf. Transmission electron 
micrograph from a pure Curosurf preparation. For details, 
see Materials and Methods. The preparations are composed 
of lamellar body-like forms (LBL), multilamellar vesicles (MV), 
and unilamellar vesicles (UV).Page 3 of 8
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The changes in biophysical activity, as measured by mini-
mum surface tension, are depicted in Figure 3B. Surfactant
in the absence of meconium reaches minimum surface
tension below 5 mN/m. Addition of meconium inacti-
vates the surface active material and causes an immediate
rise in minimum surface tension > 20 mN/m. In parallel
to the findings observed in the stereological analysis, the
addition of dextran restored the surface activity of Curo-
surf. This phenomenon could not only be observed fol-
lowing coincubation of Curosurf, meconium and dextran.
The addition of dextran to inactivated samples actually
reversed the inhibitory effects of meconium in a meco-
nium/surfactant mixture with previously disturbed bio-
physical function.
Discussion
The development of exogenous surfactant therapy for the
treatment of respiratory distress syndrome (RDS) in pre-
mature babies with primary surfactant deficiency is con-
sidered one of the major advances in neonatology in our
time [1,41,42]. Based on this success, the indications for
exogenous surfactant therapy have widened to prevent or
treat respiratory failure caused by impairment of an origi-
nally intact surfactant system like the acute respiratory dis-
tress syndrome (ARDS) and other "non-RDS" respiratory
disorders [8,16,19,32,41,43]. In these cases, however, the
efficacy of exogenous surfactant therapy depends largely
on the ability of the surfactant preparation to resist the
inactivation that caused alterations of the endogenous
surfactant system [1,17,41].
The present in vitro study demonstrates that meconium
causes alterations in the ultrastructural composition of the
modified porcine natural surfactant Curosurf that can be
visualized and analyzed qualitatively and quantitatively
using transmission electron microscopy and stereological
methods. Incubation of Curosurf with increasing concen-
trations of meconium results in an increase in the volume
fraction of unilamellar vesicles and a decrease in the vol-
ume fraction of multilamellar vesicles (resembling an
increase in the SA/LA ratio), which could be due to rela-
tive changes in particle number and/or mean particle size.
This ultrastructural finding is paralleled by an increase in
minimum surface tension. This demonstrates that the
morphological alterations observed in the present in vitro
study are relevant to biophysical surfactant function.
An increased SA/LA ratio, as demonstrated by morpholog-
ical criteria in the present study, is known to be present in
various forms of acute lung injury [8,15,32]. In general,
surfactant can be inactivated by biophysical (e.g. by com-
petition with surfactant lipids at the air-liquid interface)
or biochemical (e.g. by enzymatic degradation) mecha-
nisms. In meconium-induced surfactant inactivation,
inhibitors of surfactant function like plasma proteins
[4]or bilirubin [44]seem to be involved [18,19,43]. Meco-
nium also contains secreted phospholipase A2[45], so that
enzymatic degradation of lipids and proteins is another
inhibitory mechanism to be discussed. Recently, Kaki-
numa et al. reported an accelerated subtype conversion as
an additional mechanism for meconium-induced sur-
factant inactivation [15], indicating that also the sensitive
interaction between surfactant lipids and proteins that is
needed for the formation of the surface active film can be
disturbed by meconium.
The mechanisms by which dextran counteracts the inhib-
itory effects of meconium on surfactant function are as yet
unclear [24]. It is possible that the addition of hydrophilic
polymers lowers the energy barrier to surfactant adsorp-
tion via a nonspecific depletion attraction [46]. In our
study, dextran prevents an increased conversion of LA to
SA, thereby exhibiting a protective/stabilising effect on LA.
A similar function has been described in vivo for SP-A
[47,48]. Moreover, SP-A inhibits surfactant phospholipid
hydrolysis by secreted phospholipase A2[49]. The idea to
look for functional analogues for the carbohydrate bind-
ing domain of SP-A prompted Taeusch et al. to study the
effects of other "sugars", including dextran, on the resist-
ance of surfactant towards inhibitors [24]. For the cur-
rently available exogenous surfactant preparations that do
not contain SP-A, dextran might be a useful addition in
order to improve the maintainance of the structural and
functional integrity of surface active subtypes. Curosurf
also contains relatively little (≈1%) of SP-B and SP-C. As
surfactant subtype conversion has also been shown to be
related to loss of SP-B and surface activity in LA [5], this
might explain why natural modified surfactants that are
extracted from lung homogenate/lung lavage fluid with
organic solvents are more prone to inhibition than
"native" surfactant from amniotic fluid or lung lavage
fluid [22]. In this respect, the development of new
"designer surfactants" [21,50]with increased resistance to
inactivation seems necessary for a more successful exoge-
nous surfactant treatment of ARDS and related disorders
like meconium aspiration syndrome. Such surfactants
Table 1: Summarized stereological results
Preparation VV(LBL) [%] VV(MV) [%] VV(UV) [%] UV/
(LBL+MV)
C 26.4 46.4 27.2 0.37
CM0.02 33.1 33.1 33.9 0.51
CM0.3 38.0 22.7 39.2 0.65
CM0.3D5 42.4 27.3 30.2 0.43
CM0.3D10 43.1 29.2 27.7 0.38
Abbreviations: VV = volume fraction, LBL = lamellar body-like forms, 
MV = multilamellar vesicles, UV = unilamellar vesicles, C = Curosurf, 
M = meconium, D = dextran.Page 4 of 8
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surfactant apoproteins will be relatively expensive to pro-
duce. Dextran is cheap and it is easy to mix with sur-
factant. However, there is indication from animal work
that the effects of dextran in vivo differ between various
surfactants. In addition, dextran, due to its high osmolal-
ity, bears the risk of fluid accumulation in the lung, so that
alternatives like polyethylene glycol [30], hyaluronic acid
Ultrastructure of Curosurf, meconium, and dextranFigure 2
Ultrastructure of Curosurf, meconium, and dextran. Transmission electron micrographs from Curosurf preparations 
after incubation with 0.02 mg/ml meconium (A), 0.3 mg/ml meconium (B), 0.3 mg/ml meconium + 5 mg/ml dextran (C), and 
0.3 mg/ml meconium + 10 mg/ml dextran (D). With increasing concentrations of meconium, more unilamellar vesicles become 
visible (A and B). The flocculent material visible in the center of B most likely represents meconium material (arrow). The 
addition of increasing concentrations of dextran leads to more lamellar body like forms and less unilamellar vesicles (C and D).Page 5 of 8
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gated. The technique presented in our investigation might
be useful for such studies as well.
Conclusion
In conclusion, meconium causes alterations in the
ultrastructural composition of the natural modified sur-
factant Curosurf that can be visualized and analyzed by
TEM and stereology. These alterations resemble an
increased SA/LA ratio, indicating that an increased conver-
sion of surface active forms to inactive forms is involved
in the pathomechanism of meconium-induced surfactant
inactivation. These morphological alterations are paral-
leled by an increase in minimum surface tension. Dextran
prevents these alterations and may therefore be a useful
additive to exogenous surfactant preparations to preserve
or reconstitute their structural and functional integrity,
thereby improving their resistance to inactivation.
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